1.Clinical significance of plasma TNF-α and ET levels in patients with subarachnoid hemorrhage
Sibei JI ; Xiaojun TIAN ; Hehua LI ; Zhixiu SONG ; Kaihua ZHAI ; Mingxin MA
Clinical Medicine of China 2008;24(12):1188-1190
Objective To study the plasma TNF-α and endothelin (ET) levels in patient with subarach-noid hemorrhage(SAH). Methods The plasma TNF-α and ET levels were measured by ELISA and radioimmunity at 1,3,7,14 and 21 d after onset of SAH in 45 patients. Results The plasma TNF-α and ET levels in patients with SAH were higher than the normal controls(P<0.01),among which the highest levels appeared at 3 d and 7 d,and the levels of plasma TNF-α and ET in patients with SAH were decreased at 14 d. Those of high Hunt-Hess grade~groups was higher than those of lower grade~groups(P<0.01). Conclusion The plasma TNF-α and ET levels are significantly elevated in the patients with SAH,which suggests that TNF-α and ET may play an important role in the pathogenesis of SAH,and which suggests that is one of the possible ways to prevent and treat cardiovascular spasm (CVS) after SAH by inhibiting TNF-α and ET.
2.Levels of platelet-leukocyte aggregates in patients with delayed encephalopathy after acute carbon monoxide poisoning
Ankui JIA ; Yanxuan LIU ; Sibei JI ; Guolin ZHANG ; Hua ZHONG ; Guangxia XU
Chinese Journal of Neuromedicine 2014;13(1):80-82
Objective To investigate the circulating levels of platelet-leukocyte aggregates (PLA) in patients with delayed encephalopathy after acute carbon monoxide poisoning (DEACMP).Methods The circulating levels of platelet-neutrophil aggregates (PNA) and platelet-monocyte aggregates (PMA) were quantified in 30 patients with DEACMP (DEACMP group) and 30 patients with acute carbon monoxide poisoning (ACOP group) by using flow cytometry assay,whose results were compared with those of 20 healthy subjects (controls).Results Circulating PNA and PMA levels in DEACMP group and ACOP group at acute stage were significantly higher than those in controls,respectively (P<0.05),while no significant difference was noted between ACOP group and DEACMP group at acute stage (P>0.05),indicating that platelets were in activation status and PLA levels raised significantly in patients with DEACMP and ACOP at acute stage.Circulating PNA and PMA levels were significantly higher in DEACMP group at acute stage than those in DEACMP group at stable stage (P< 0.05),suggesting that platelet activation were controlled after the illness state were stabilized in patients with DEACMP.Conclusion Platelet is involved in the pathogenesis of DEACMP and the change trend of circulating PLA levels is basically consistent with illness state.
3.Correlation between serum matrix metalloproteinase-9 level and location and severity of bleeding in patients with cerebral microbleeds
Xue PENG ; Lifang MENG ; Hao LIU ; Jin WANG ; Junli LIU ; Xianglei JIA ; Panpan ZHAO ; Fan WANG ; Chaowei WANG ; Junyan YUE ; Jian ZHANG ; Sibei JI ; Bin YUAN ; Ruiyan CAI ; Shaomin LI ; Jianhua ZHAO
Chinese Journal of Behavioral Medicine and Brain Science 2021;30(3):244-249
Objective:To investigate the relationship between serum matrix metalloproteinase-9 (MMP-9) level and the location and severity of bleeding in patients with cerebral microbleeds(CMBs).Methods:A total of 60 CMBs patients admitted to the Department of Neurology of the First Affiliated Hospital of the Xinxiang Medical University from January 2019 to August 2020 were selected as subjects as the CMBs group, and 60 healthy controls without nervous system diseases in outpatient physical examination during the same period were selected as the control group. The clinical data and biochemical indicators of the two groups were collected. Serum MMP-9 levels were measured by enzyme linked immunosorbent assay (ELISA). According to susceptibility weighted imaging (SWI), CMBs patients were divided into grade 1 group ( n=24), grade 2 group ( n=19) and grade 3 group ( n=17), and according to the micro analytical rating scale (MARS), the CMBs patients were divided into the lobar group ( n=19), the deep or infratentorial group ( n=17) and the mixed group ( n=24).The relationship between serum MMP-9 level and the location and severity of CMBs was analyzed. SPSS 19.0 software was used for data statistical analysis.One-way ANOVA, t-test and rank sum test were used for comparison. Logistic regression analysis was used to analyze the influencing factors. Pearson correlation analysis and Spearman correlation analysis were used for correlation analysis. Results:The level of MMP-9 in CMBs group was significantly higher than that in control group (208.13(142.25, 285.88) μg/L, 149.50(93.40, 186.51)μg/L), and the difference was statistically significant ( P<0.05). Serum MMP-9 level was a risk factor of CMBs ( β=1.322, OR=3.750, 95% CI=2.038-7.997, P=0.002). The difference of level of MMP-9 in different severity of CMBs was statistically significant (147.55(109.25, 266.47)μg/L, 242.12(147.55, 288.80)μg/L, 270.42(203.43, 364.27)μg/L, P=0.017). Serum MMP-9 level was positively correlated with the number of CMBs ( r=0.371, P=0.003). The difference of MMP-9 level of CMBs in different locations were statistically significant (249.77(158.43, 338.46)μg/L, 188.83(138.52, 243.15)μg/L, 210.65(144.25, 255.78)μg/L, P=0.013). The increased serum MMP-9 level was a risk factor for CMBs( β=0.401, OR=1.122, 95% CI=1.004-1.204, P=0.036). Conclusion:The increased level of serum MMP-9 may be a risk factor of CMBs, especially for CMBs in cerebral lobesand, and the level of MMP-9 is positively correlated with the severity of CMBs.
4.Clinical analysis of 26 cases of dementia with Lewy bodies
Chaowei WANG ; Sibei JI ; Yanxia LIU
Journal of Apoplexy and Nervous Diseases 2020;37(10):924-926
Objective To investigate the clinical and neuroimaging features of dementia with Lewy bodies (DLB).Methods The clinical data of 26 patients with DLB were retrospectively analyzed.Results The initial symptoms were cognitive symptoms (65%),Parkinsonism (19%),or both.In the clinical manifestations,38% of patients showed fluctuating cognition,77% showed Parkinsonism,62% showed hallucinations,and 50% showed rapid eye movement sleep behavior disorder,65% showed severe autonomic dysfunction.59% of the patients revealed the preservation of hippocampal structures on MRI scan.In addition,FDG PET showed hypo-metabolism in bilateral parietal and occipital lobe in 7 patients,and CFT PET demonstrated reduced dopamine transporter uptake in the basal ganglia in 2 patients.Conclusion Cognitive impairment was the initial symptoms in most patients with DLB,and the clinical symptoms were characterized by Parkinsonism,hallucinations,rapid eye movement sleep behavior disorder and psychiatric symptoms.Neuroimaging examination including MRI and PET scan were useful to diagnose.
5.Correlation between serum MMP-9 protein level and vascular cognitive impairment with no dementia in patients with cerebral small vessel diseases
Jianhua ZHAO ; Xue PENG ; Lifang MENG ; Hao LIU ; Jin WANG ; Shaomin LI ; Junli LIU ; Xianglei JIA ; Panpan ZHAO ; Fan WANG ; Chaowei WANG ; Lijun ZHANG ; Qing LI ; Jing REN ; Sibei JI ; Bin YUAN
Chinese Journal of Behavioral Medicine and Brain Science 2020;29(9):808-812
Objective:To investigate the relationship between serum matrix metalloproteinase-9(MMP-9) level and vascular cognitive impairment with no dementia (VCIND) in patients with cerebral small vessel diseases (CSVD).Methods:A total of 374 patients with CSVD treated in the First Affiliated Hospital of Xinxiang Medical University from January 2016 to January 2020 were collected and 150 healthy subjects in the same period were used as general data of the control group. All subjects were detected for serum MMP-9 level using enzyme linked immunosorbent assay and received cognitive function scoring using Montreal cognitive assessment (MoCA). The 374 patients with CSVD were divided into the Group A(186 cases with vascular cognitive impairment with no dementia) and the Group B(188 cases without cognitive impairment). The general data, serum MMP-9 level and cognitive function score were compared among the three groups and the correlation between MMP-9 level and cognitive function was analyzed.Results:The MMP-9 levels of Groups A and B ( (335.10±105.10)μg/L, (261.62±80.32)μg/L) were higher than those of the control group ( (168.23±48.85)μg/L), and the MMP-9 level of Group A was higher than that of Group B ( P<0.05). The MoCA scores of Groups A and B ( (18.45±5.24), (28.31±1.52) ) were lower than those of the control group (29.49±0.90), and the MoCA scores of Group A were lower than those of Group B ( P<0.05). The serum MMP-9 level, a risk factor for VCIND in patients with CSVD ( β=1.505, OR=1.323, 95% CI=1.149-1.527, P<0.05), was negatively correlated with total score of MoCA scale, visual-spatial and executive function, naming, language, abstract thinking, delayed recall, and directive force factor score ( r=-0.299, r=-0.155, r=-0.383, r=-0.358, r=-0.192, r=-0.259, r=-0.246 respectively, all P<0.05). Conclusion:The increased level of MMP-9 may be a risk factor of VCIND in CSVD patients, and it is closely related to cognitive impairment.
6.Correlation between serum VEGF level and white matter hyperintensity and cognitive dysfunction in patients with cerebral small vessel disease
Jin WANG ; Jianhua ZHAO ; Hao LIU ; Junli LIU ; Fangli YANG ; Qiong LI ; Minghua WANG ; Panpan ZHAO ; Fan WANG ; Qing LI ; Zhixiu XU ; Junyan YUE ; Jian ZHANG ; Sibei JI ; Ruiyan CAI ; Shaomin LI
Chinese Journal of Behavioral Medicine and Brain Science 2022;31(4):333-340
Objective:To investigate the relationship between serum vascular endothelial growth factor (VEGF) levels and white matter high signal and non-dementia vascular cognitive dysfunction in patients with cerebral small vascular disease (CSVD).Methods:Total 106 patients with CSVD who were admitted to the Department of Neurology of the First Affiliated Hospital of Xinxiang Medical College from April 2019 to December 2020 were enrolled.They were divided into vascular cognitive impairment no dementia group (VCIND group, n=47) and no vascular cognitive impairment group (N-VCI group, n=59)according to mini-mental assessment scale (MMSE), Montreal cognitive assessment (MoCA) scale and activity of daily living scale (ADL). Serum VEGF levels were detected by enzyme-linked immunosorbent assay (ELISA). The baseline data, serum VEGF levels, MoCA score and Fazekas score were compared between the two groups.The correlation between serum VEGF level and white matter high signal and cognitive function was analyzed.SPSS 19.0 software was used for data processing.The statistical methods were t-test, Chi square test, nonparametric test, Logistic regression analysis, Pearson correlation analysis and Spearman correlation analysis. Results:There were significant differences in serum VEGF level((464.18±114.58)pg/mL, (414.17±45.80)pg/mL, F=22.880), MoCA score((13.07±6.48), (20.17±4.06), F=17.920) and Fazekas score (4(3, 5), 3(1, 3), Z=-4.189)between the two groups (all P<0.05). The level of VEGF( β=0.008, OR=1.008, 95% CI=1.001-1.015, P<0.05) was the influencing factor of cognitive function in patients with CSVD .The level of VEGF was negatively correlated with the total score of MoCA, attention and calculation power, and orientation ability ( r=-0.345, -0.373, -0.445, all P<0.05) and it was positively correlated with the total Fazekas score and the Fazekas score of paraventricular and deep white matter ( r=0.392, 0.495, 0.302, all P<0.05). There was a linear trend between the high signal grade of paraventricular and deep white matter and VCIND (both P<0.05). Conclusion:Serum VEGF level is correlated with cognitive function and white matter hyperintensity in patients with CSVD.The increase of VEGF level may be a factor reflecting cognitive dysfunction.In addition, with the increase of white matter hyperintensity level, the risk of VCIND in CSVD is increased.
7.Correlation between serum GDNF level and neuroimaging changes and cognitive impairment in patients with cerebral small vessel disease
Fangli YANG ; Hao LIU ; Fan WANG ; Qing LI ; Xiyan CHEN ; Ruiyan CAI ; Qingwu WU ; Jian ZHANG ; Sibei JI ; Chengbiao LU ; Shaomin LI ; Jianhua ZHAO
Chinese Journal of Behavioral Medicine and Brain Science 2023;32(9):809-815
Objective:To investigate the relationship between serum glial cell line-derived neurotrophic factor (GDNF) levels and neuroimaging changes and cognitive impairment in patients with cerebral small vascular disease (CSVD).Methods:135 patients with CSVD recruited from the Department of Neurology of the First Affiliated Hospital of Xinxiang Medical University from September 2021 to July 2022 were assessed by cranial multimodal magnetic resonance imaging and Montreal cognitive function assessment (MoCA), and the basic data were analyzed at the same time.The serum GDNF concentration of all patients was detected by enzyme-linked immunosorbent assay (ELISA). According to the median GDNF concentration, the patients were divided into low GDNF group and high GDNF group. The baseline data, MoCA score and imaging markers of the two groups were compared by Mann-Whitney U test, chi-square test, logistic regression, Kruskal-Wallis H test and Jonckheere-Terpstra trend test, and the correlation between serum GDNF level and imaging markers and cognitive function of patients with CSVD was analyzed. Results:The median serum GDNF concentration of all CSVD patients was 16.66 pg/mL. Multivariate logistic regression analysis showed that low serum GDNF level was a risk factor for white matter hyperintensity and total image load in patients with CSVD. Serum GDNF level was a protective factor of cognitive impairment in patients with CSVD in multiple logistic regression analysis. The area under the curve of ROC curve analysis of cognitive impairment after CSVD predicted by serum GDNF level was 0.735, the sensitivity was 66.4%, and the specificity was 71.4%. The level of serum GDNF was positively related with visual space and executive function, attention and computational power, delayed recall and orientation( r=0.267, 0.187, 0.219, 0.215, all P<0.05). Conclusion:The serum GDNF level is related to white matter hyperintensities, total imaging load and cognitive impairment in patients with CSVD. Serum GDNF level may play a predictive role in CSVD and cognitive impairment.